非ST段抬高型急性冠脉综合征患者血浆S100A1水平与GRACE评分及短期预后相关性的研究

Association between the Level of Serum S100A1 and GRACE Score and Short-term Prognosis in Patients with NSTE-Acute Coronary syndrome

目的:探讨非ST段抬高型急性冠脉综合征(NST-ACS)患者血浆S100A1水平与全球急性冠状动脉事件注册(GRACE)评分之间的关系,以及S100A1水平对NST-ACS患者30天预后的判定价值。方法:共有162例NST-ACS患者符合入选标准,收集基本临床资料,进行GRACE评分,同时收集次日清晨空腹采集肘静脉血,检测血浆S100A1浓度,与患者的GRACE评分进行比较。根据S100A1的水平进行分组随访,KM生存分析不同组患者30天预后进行评价。结果:不同GRACE分组患者间S100A1水平具有显著性差异(P<0.05);相关性分析显示,NST-ACS患者S100A1与GRACE评分呈显著正相关(r=0.49,P<0.01);KM生存分析显示,S100A1水平>3.41 ng/mL的患者30天内心血管事件发生率显著升高(P<0.05)。结论:S100A1可作为预测NST-ACE患者病情的发生发展的生化指标;在NST-ACS患者中运用S100A1有助于对患者早期危险分层及评估预后有一定的临床价值。

Objective: Acute coronary syndrome(ACS) is associated with several clinical syndromes, one of which is acute nonST-segment elevation myocardial infarction(NST-ACS). S100A1 is a calcium-dependent regulator of heart contraction and relaxation.We investigated the association between serum S100A1 levels and the global acute coronary event registration(GRACE) risk score in patients with NST-ACS and the potential of using serum S100A1 to predict the 30-day prognosis of NST-ACS. Methods: A total of 162 patients with NST-ACS were enrolled, and their clinical characteristics were analyzed to determine the GRACE score. The serum S100A1 concentration was determined using fasting antecubital venous blood. The patients were divided into different groups according to serum S100A1 levels, and the 30-day NST-ACS prognosis was evaluated using Kaplan-Meier analysis. Results: The serum S100A1 levels differed significantly among the groups(P<0.05). Correlation analysis showed that serum S100A1 levels were positively correlated with the GRACE score(r=0.49, P<0.01);Kaplan-Meier analysis revealed that the number of 30-day cardiac events was significantly higher in patients with S100 A1 level >3.41 ng/mL(P<0.05). Conclusions: S100A1 is a potential biomarker that can predict the progression of NST-ACS and aid in its early risk stratification and prognosis.